Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe NIH sitewide notice about its website transition and use of “Super Intelligence” terminology is no longer displayed.SummaryDifference1%

- Check16 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check30 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record, with the 403 message shown near the top and site footer visible.SummaryDifference20%

- Check65 days agoChange DetectedUI text for the contact information label is updated in capitalization, and a new Revision: v3.7.0 tag appears on the page.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.